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KEY POINTS 
• Current epidemiological studies of the association between antihypertensive drugs 
and keratinocyte carcinoma (KC) risk offer inconsistent results.  
• Use of diuretics might be associated with an increased risk of KC, while ACE 
inhibitors or ARBs might be associated with a decreased risk of KC in patients at 
high risk.  
• Use of β-blockers and CCBs might be associated with an increased risk of BCC but 
not SCC. 
• Further post-marketing surveillance studies are warranted to confirm our findings. 
WORD COUNT: 3101 
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ABSTRACT 
Purpose Current epidemiologic evidence on the association between antihypertensive 
drugs and keratinocyte carcinoma (KC) risk is inconsistent. We sought to quantify this 
association by meta-analysis of observational studies. 
Methods We systematically reviewed observational studies published through August 
2016 and reported the KC risk (basal cell carcinoma/BCC and squamous cell 
carcinoma/SCC) associated with antihypertensive drugs, including diuretics, 
angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor 
blockers (ARBs), beta-adrenergic blocking agents (β-blockers), and calcium channel 
blockers (CCBs). Random-effects meta-analysis was used to estimate the odds ratio 
(OR) with 95% confidence interval (CI).  
Results Ten eligible studies were included. Compared with non-use, diuretic use was 
significantly associated with increased risk of both BCC (OR, 1.10; 95% CI, 1.01 to 
1.20) and SCC (OR, 1.40; 95% CI, 1.19 to 1.66). Use of β-blockers or CCBs was 
slightly associated with increased risk of BCC (but not SCC); the OR with β-blockers 
was 1.09 (95% CI, 1.04 to 1.15) and with CCBs was 1.15 (95% CI, 1.09 to 1.21). Use of 
ACE inhibitors or ARBs was associated with decreased risk of both BCC (OR, 0.53; 
95%CI, 0.39 to 0.71) and SCC (OR, 0.58; 95%CI, 0.42 to 0.80) in high-risk individuals.  
Conclusions Current evidence indicates that use of diuretics might be associated with 
an increased risk of KC, while ACE inhibitors or ARBs might be associated with a 
decreased risk in high-risk individuals. β-blockers or CCBs might be positively 
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associated with BCC risk. Further post-marketing surveillance studies and 
investigations to clarify the possible underlying mechanisms are warranted.
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INTRODUCTION 
Keratinocyte carcinoma (KC), the most common type of skin cancer, generally refers to 
basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The incidence of 
NMSC has been increasing steadily, e.g., the US alone had an estimated incidence of 
3.5 million in 2006, which grew to 5.4 million by 20121. Although the mortality 
associated with KC is relatively low, the substantial associated morbidity translates to a 
considerable number of cases, and therefore an enormous burden in healthcare costs 2. 
KC is caused mainly by exposure to ultraviolet radiation (UVR) 3, 4, though other 
postulated risk factors include fair skin, red hair, smoking, alcohol consumption, obesity, 
and drug use5-8.  
A number of antihypertensive drugs have been approved and widely used for treating 
hypertension, which affects up to 60 million people in the US9. Several classes of 
antihypertensive drugs (e.g., diuretics) are described as being photosensitizing 10, 11 and 
may also have phototoxic effects upon UVR exposure, increasing the risk of developing 
UVR-related KC 12. However, the mechanism of action is poorly understood. Drug-
induced photosensitivity is influenced by the chemical structure of the drug and 
determined by its capacity to modify an individual’s sensitivity to UVR. Current findings 
regarding the risk of KC have been inconsistent across the classes of antihypertensive 
drugs. Elevated risk of BCC associated with diuretic use has been observed especially 
in overweight and obese individuals 13. More recently, several case-control studies 
found that long-term use of diuretics was associated with increased risk of SCC 14, 15.. 
However, one cohort study in Danish patients found no association between increased 
risk of KC and long-term daily use of diuretics 17. In contrast, reduced risk of KC has 
6  
been associated with the use of both angiotensin-converting enzyme inhibitors (ACE 
inhibitors) and angiotensin receptor blockers (ARBs) 18. Little is known about the 
association between beta-adrenergic blocking agents (β-blockers) or calcium channel 
blockers (CCBs) and KC risk. The inconsistent results might be due to limited 
information from individual studies, including small sample size, short follow-up, and 
variation in geographic region. We therefore examined whether use of any of the 
following five major classes of antihypertensive drugs – ACE inhibitors, ARBs, β-
blockers, CCBs, or diuretics – was associated with KC risk by meta-analysis of 
observational studies. 
METHODS 
The study was performed in accordance with the Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines for reviews of observational studies 19  
Search strategy and study selection  
We systematically searched PubMed, Embase, and Cochrane Central Register of 
Controlled Trials (CENTRAL) from inception to August 12, 2016 to identify observational 
studies (cohort studies and case-control studies) evaluating the association between 
exposure to antihypertensive drugs and risk of KC. Combined terms were used to 
search these databases without any restriction (File S1). We also manually checked the 
reference lists of relevant reviews and meta-analyses to identify additional studies. Two 
reviewers (HT and SF) independently selected the studies according to the following 
criteria: 1) clearly defined the exposure to antihypertensive drugs; 2) “no use of 
antihypertensive drug” as the reference; 3) reported the outcome of KC (including BCC 
or SCC); 4) reported the odds ratio (OR), risk ratio (RR), and hazard ratio (HR) with 
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corresponding 95% confidence intervals (CIs), or sufficient data to calculate; and 5) 
cohort studies or case-control studies. We excluded abstracts and unpublished studies 
due to lack of information about patient and study characteristics. For the same sample 
used in multiple reports, only the latest or longest follow-up study was included. In the 
case of any missing information, we contacted the original author for clarification.   
Data extraction and quality assessment  
Two reviewers (HT and SF) independently extracted data and assessed the quality of 
each study. We collected the following information: study design, region of study, drug 
use and reference, characteristics of participants, selection criteria, exposure definition, 
adjusted covariates, and the adjusted estimates of KC. In additional, we assessed the 
quality of studies using the Newcastle-Ottawa quality-assessment scale (NOS) based 
on the following three domains: selection, comparability, and exposure/outcome20. The 
total NOS score ranges from 0 to 9, with a higher score indicating greater quality. The 
studies with scores of 0 to 5, 6 to 7, and 8 to 9 were considered low, moderate, and high 
quality, respectively. Any disagreements were resolved by consensus or referral to a 
third reviewer (JH).  
Statistical analysis  
ORs with 95% CI were used to estimate the risk of KC associated with antihypertensive 
drugs. Considering heterogeneity across studies, a random-effects meta-analysis model 
was used to calculate the estimates separately for ACE inhibitors, ARBs, β-blockers, 
CCBs, and diuretics. The I² statistic was used to assess heterogeneity, with I2 of <25%, 
≥25% and <75%, and ≥75% indicating low, moderate, and high heterogeneity, 
respectively 21. Subgroup analysis was used to assess the consistency of associations 
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between each class of antihypertensive drug and risk of KC within certain pre-specified 
subgroups: type of design (cohort study vs. case-controlled study), region of study 
(Europe vs. USA), study quality (high quality vs. moderate quality), adjusted for sun or 
UVR exposure (yes vs. no), and adjusted for smoking (yes vs. no) if there were 
sufficient data (at least six studies included22). We performed a cumulative meta-
analysis to evaluate the development of evidence over time by adding one study at a 
time in the order of date of publication. A sensitivity analysis was carried out to assess 
the robustness of our findings by removing one study at a time. In addition, publication 
bias was assessed using Begg’s and Egger’s tests. All statistical analyses were 
performed with STATA (Version 14; Stata Corp., College Station, TX). A p value <0.05 
was considered significant. 
RESULTS 
Of 2430 unique citations retrieved from electronic databases, ten observational studies, 
i.e., six cohort studies13, 17, 18, 23-25 and four case-control studies12, 14, 26, 27, met the 
eligibility criteria and were included in our meta-analysis (Figure 1). The basic 
characteristics of the included studies are presented in Table 1. Studies were published 
between 2008 and 2016; six were carried out in Europe and four in the United States. It 
should be noted that one study25 was conducted among renal transplant recipients and 
another study18 included veterans at high risk for BCC and SCC, which was defined as 
experiencing at least two BCCs and/or SCCs in the five years preceding the study 
period. Diuretics were analyzed in nine studies, ACE inhibitors in two, ARBs in two, 
ACE inhibitors or ARBs as a category in two, β-blockers in three, and CCBs in three. 
The included studies were of moderate or high quality, with five assessed as high 
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quality (8 out of 9 using NOS), and the other five studies were assessed as medium 
quality (NOS score from 6 to 7) (Table S1). 
Use of diuretics and KC risk 
Eight studies 12-14, 17, 18, 23, 24, 27 reported an association between diuretic use and risk of 
BCC. Meta-analysis of these studies showed that use of diuretics was significantly 
associated with an increased risk of BCC compared with non-use (OR, 1.10; 95% CI, 
1.01 to 1.20) (Figure 2A). There was significant heterogeneity among studies (I2 = 
82.2%). The results from subgroup analysis are presented in Table 2. A significantly 
increased risk of BCC was observed in cohort studies (OR, 1.09; 95% CI, 1.04 to 1.13), 
studies of moderate quality (OR, 1.47; 95% CI, 1.04 to 2.07), or in studies with (OR, 
1.07; 95% CI, 1.01 to 1.12) or those without adjusting for smoking status (OR, 1.14; 
95% CI, 1.02 to 1.29). Our cumulative meta-analysis showed that the cumulative OR 
became significant when the study published by Nardone et al. in 2016 was added 
(Figure 3A). A sensitivity analysis excluding one study at a time indicated that our 
results are robust unless the study by Nardone et al. 2016 was excluded (Figure S1A). 
There was no evidence of publication bias based on Egger’s test (P = 0.20) or Begg’s 
test (P = 0.27).  
Seven studies 12, 14, 17, 18, 24, 26, 27 provided estimates of the association between diuretics 
and SCC risk. Meta-analysis of these studies showed that use of diuretics was 
significantly associated with an increased risk of SCC compared to non-use (OR, 1.40, 
95% CI, 1.19 to 1.66) (Figure 2B). There was significant heterogeneity among studies 
(I2 = 81.8%). Our subgroup analysis did not found a significantly increased risk of SCC 
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in US populations, in studies adjusted for sun or UVR exposure, and studies adjusted 
for smoking status (Table 2). Our cumulative meta-analysis showed that the cumulative 
OR including the second study in 2008 became significant (OR, 1.19; 95% CI, 1.04 to 
1.36) (Figure 3B). Since then, the cumulative OR remained significant and stable. In 
addition, a sensitivity analysis excluding one study at a time did not significantly affect 
the pooled estimates (Figure S1B). There was no evidence of publication bias based 
on Egger’s test (P=0.30) or Begg’s test (P=0.23).  
Use of ACE inhibitors or ARBs and KC risk 
Two studies 14, 24 reported on the association between ACE inhibitors and risk of BCC or 
SCC (Figure 2), one of which found a significantly increased risk 24. However, when we 
conducted a pooled analysis of the data from these two studies, there was no significant 
association between ACE inhibitors and risk of BCC (OR, 1.50; 95% CI, 0.70 to 3.22) or 
SCC (OR, 1.42; 95% CI, 0.81 to 2.50). In addition, significant heterogeneity was 
detected for BCC (I2 = 97.6%) and SCC (I2 = 88.6%). Further analysis (e.g., subgroup 
analysis) was not possible due to the limited number of studies included. 
Two studies 14, 24 examining the risk of BCC and SCC associated with ARBs had 
inconsistent results (Figure 2), one of which indicated significantly increased risk 24. 
Pooled analysis of these two studies identified no significant association between use of 
ARBs and risk of BCC (OR, 1.75; 95% CI, 0.68 to 4.49) or SCC (OR, 1.54; 95% CI, 0.82 
to 2.90). There was significant heterogeneity for both BCC (I2 = 97.4%) and SCC (I2 = 
83.1%).  
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Two studies 18, 25 provided data on the association between use of ACE inhibitors or 
ARBs as a category and risk of KC in renal transplant recipients or patients at high risk 
for KC (Figure 2). Both studies found a lower risk of BCC and SCC among patients 
using ACE inhibitors or ARBs18, 25. Our meta-analysis showed that use of ACE inhibitors 
or ARBs was significantly associated with a decreased risk of both BCC (OR, 0.53; 95% 
CI, 0.39 to 0.71) and SCC (OR, 0.58; 95% CI, 0.42 to 0.80) as compared to non-use 
(Figure 2).  
Use of β-blockers and KC risk 
Three studies 14, 18, 25 presented adjusted estimates of the association between use of β-
blockers and risk of BCC or SCC (Figure 2). When we performed a pooled analysis of 
these three studies, we found that β-blockers were significantly associated with 
increased risk of BCC compared with non-use (OR, 1.09; 95% CI, 1.04 to 1.15), while 
there was no significant association between use of β-blockers and risk of SCC (OR, 
0.89; 95% CI, 0.69 to 1.16). We detected no heterogeneity across studies for BCC (I2 = 
0%) and only moderate heterogeneity for SCC (I2 = 68.1%). 
Use of CCBs and KC risk 
Three studies 14, 18, 25 assessed the association between CCBs and risk of BCC or SCC 
(Figure 2). Based on their data, use of CCBs was significantly associated with 
increased risk of BCC compared with non-use (OR, 1.15; 95% CI, 1.09 to 1.21), with no 
evidence of heterogeneity (I2 = 0%). However, there was no significant association 
between use of CCBs and risk of SCC (OR, 1.03; 95% CI, 0.88 to 1.21), with low 
evidence of heterogeneity (I2 = 29.3%). 
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DISCUSSION 
In this meta-analysis of ten observational studies, we found that use of diuretics was 
significantly associated with increased risk of KC, with a 10% increased risk for BCC 
and 40% increased risk for SCC. However, there was significant heterogeneity among 
studies in the overall and subgroup analyses. There was no significant association 
between diuretics and risk of KC (including SCC) in studies that adjusted for sun or 
UVR exposure. Our cumulative meta-analysis indicated that the cumulative OR of the 
association between use of diuretics and risk of SCC and BCC first became significant 
in 2008 and in 2016, respectively. There was some evidence of a slightly but 
significantly increased risk of BCC among patients using β-blockers or CCBs. The use 
of ACE inhibitors or ARBs might be associated with a decreased risk of KC in renal 
transplant recipients or patients at high risk for KC. However, the results of our meta-
analysis should be interpreted with caution due to significant heterogeneity and the 
limited number of studies included.   
Our findings are in agreement with several previous studies suggesting increased risk of 
KC among users of diuretics14, 24. Moreover, the cumulative meta-analysis showed that 
the increased risk of SCC was evident from 2008 onwards, and the effect was robust 
and unlikely to be a chance finding. A recent matched cohort study performed in a large 
electronic medical records repository of the Northwestern Medicine Enterprise Data 
Warehouse (NMEDW) found that use of thiazide diuretics was associated with 
increased OR for development of both BCC and SCC 24. Similarly, a case-control study 
performed in northern Demark found a significantly increased risk of SCC and a 
borderline increase in risk of BCC among patients taking diuretics 14. These findings 
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raise the possibility that KC risk is elevated among users of diuretics, especially thiazide 
diuretics. In addition, we found a non-significantly increased risk of KC (especially SCC) 
in studies that adjusted for sun or UVR exposure. It is well known that diuretics can act 
as co-carcinogens with UVR to promote KC development 12. The photosensitizing 
reaction followed by sun or UVR exposure can exacerbate the risk of sunburn and 
photo-damage and ultimately increase risk of KC among patients taking diuretics28. 
However, the results from prior studies varied for BCC and SCC. A multicenter hospital-
based case-control study in European populations found that users of diuretics had 
increased risk of SCC, but not BCC 27. Another population-based case-control study 
showed a significant association between use of diuretics and development of SCC, but 
not BCC 12. In our meta-analysis, we also found a stronger association with SCC (OR, 
1.40) than with BCC (OR, 1.10) among patients taking diuretics, and our cumulative 
meta-analysis indicated that the significantly increased risk of SCC has been observed 
since 2008, while the increased risk of BCC became evident starting only in 2016. One 
possible explanation might be that chronic UV exposure is more strongly related to risk 
of SCC than BCC29. Further studies on effect modification of UV exposure on these 
drugs with skin cancer risk are warranted. 
Though smoking is a well-known risk factor for many human cancers30, findings 
regarding potential associations between smoking and KC risk remain inconsistent 31. 
Our subgroup analysis found a significantly increased risk of BCC and a non-
significantly increased risk for SCC in the studies adjusted for smoking status, indicating 
that smoking is not likely to be a major confounder for KC risk. Our stratified analysis by 
geographic region indicated that use of diuretics was significantly associated with 
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increased risk of SCC in European populations, but not in US populations. However, a 
non-significantly increased BCC risk was observed in both populations. Further large, 
well-conducted studies adequately adjusting and stratifying for major confounders (e.g., 
UVR exposure) are required to confirm our findings.  
Our meta-analysis of three studies14, 18, 25 found a slight but significant association 
between increased risk of BCC and use of β-blockers or CCBs. The underlying 
mechanism of action is unclear. Some specific drugs in the classes of β-blockers (e.g., 
sotalol) or CCBs (e.g., nifedipine) are considered photosensitizing agents 32 and 
therefore might increase KC development by acting as co-carcinogens with UVR. 
However, there was no significant difference between CCBs and β-blockers in terms of 
SCC risk. In addition to the fact that only three studies were included, it should be noted 
that the significant association was largely driven by one study performed by Schmidt et 
al14. The KC risk associated with CCBs or β-blockers remains uncertain and therefore 
requires exploration in more well-conducted studies. 
Use of ACE inhibitors or ARBs might be associated with lower risk of KC in renal 
transplant recipients or patients at high risk for KC. No significant difference was 
observed in other populations. Little is known about the possible mechanisms 
underlying any carcinogenic risk associated with ACE inhibitors or ARBs. Some 
evidence from experimental studies and epidemiologic studies has suggested 
chemopreventive effects of ACE inhibitors and ARBs against cancer, with possible 
mechanisms of actions including inhibition of matrix metalloprotease activity, reduced 
expression of vascular endothelial growth factor, and interference with the renin-
angiotensin system33. However, ACE inhibitors or ARBs have been reported to have 
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photosensitizing potential 32, and one matched-cohort study found significantly 
increased risk of KC among patients taking these drugs 24. Therefore, future studies are 
warranted to clarify the association between use of ACE inhibitors or ARBs and 
development of KC. 
Our study has two strengths. First, we systematically searched electronic databases to 
include all relevant studies. It is important to note that this is the first meta-analysis to 
address the association between antihypertensive drugs and risk of KC. Second, to 
confirm the robustness of our findings, pre-specified subgroup analysis and sensitivity 
analysis were performed if there were sufficient data. However, our meta-analysis also 
has several potential limitations. First, because there was a lack of information in the 
eligible studies about the common risk factors for KC, such as UVR exposure, ethnicity, 
and smoking status, we extracted the adjusted estimates for potential confounders (e.g., 
UVR exposure) whenever available and further conducted a subgroup analysis to 
minimize bias. Second, one potential confounder, health-seeking behaviors, may lead to 
detection bias. Individuals under hypertension management may be more likely to seek 
medical advice and be subject to increased surveillance, increasing the likelihood of 
disease diagnosis. However, we did not detect an increased risk of KC across all 
classes of antihypertensive drugs, which suggested that the increased risk might not be 
entirely due to increased scrutiny. Third, information about cumulative doses and 
cumulative durations were unavailable from the selected studies, preventing us from 
performing a further dose-response analysis. Finally, there was some evidence of 
significant heterogeneity across studies. Though we explored possible sources of 
heterogeneity by performing several subgroup analyses, we could not completely 
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exclude heterogeneity. Additionally, the limited number of studies included made us 
unable to perform this analysis for β-blockers, ACE inhibitors, ARBs, or CCBs.  
In summary, this meta-analysis based on evidence from ten observational studies 
indicated that use of diuretics might be associated with increased risk of KC, while use 
of ACE inhibitors or ARBs might be associated with decreased risk in patients at high 
risk. In addition, use of β-blockers or CCBs might be associated with increased risk of 
BCC. Because our study was observational, these results should be interpreted with 
caution and are insufficient evidence to alter current clinical recommendations. 
Nevertheless, these data support continued investigation of the potential mechanisms 
underlying this relationship.  
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Table 1. Characteristics of included studies 1 
Study Study 
design  
Data source Follow-up 
(years) 
No. of 
participants  
Age 
(year) 
Male 
(%) 
Selection criteria Exposure 
definition 
Adjustment covariates 
Jensen et al. 
200812 
Case-
control 
study 
Danish Cancer 
Registry; North 
Jutland County; 
1989 to 2003; 
Denmark 
NR MM: 1010; 
BCC: 594; 
SCC: 1129;  
Controls: 
32,412 
NR NR Patients registered with a 
first primary diagnosis of 
BCC, SCC, or MM, and 
four population controls 
selected for each case 
Use of  
diuretics 
Prior hospitalization for 
selected chronic diseases 
and use of glucocorticoids. 
De Vries et al. 
201227 
Case-
control 
study 
Multicenter, 
hospital-based, 
case–control 
study was carried 
out in Finland, 
Germany, Greece, 
Italy, Malta, 
Poland, Scotland, 
and Spain; NR; 
Europe 
NR MM:360; 
SCC:409; 
BCC:602; 
Controls:155
0 
67 56 Patients recently 
diagnosed with SCC, 
BCC, or MM (≥18 years) 
and matched controls 
Use of 
thiazide 
diuretics 
at least 
for 3 
months 
Age, sex, phototype, and 
country 
Robinson et 
al. 201326 
Case-
control 
study 
New Hampshire 
residents enrolled 
in the Center for 
Medicare and 
Medicaid 
Services; 1993 to 
2000; 2001 to 
2009; US 
NR BCC:1567; 
SCC:1599; 
Controls:190
6  
NR 56.4 BCC and SCC cases, 
matched controls 
identified from New 
Hampshire residents who 
speak English, have a 
listed telephone number, 
and were between 25 
and 74 at diagnosis 
Use of 
diuretics 
Age, sex, number of painful 
sunburns, and study phase 
in final models; other 
confounder effects 
including the lifetime hours 
of warm months sun 
exposure, skin response to 
first hour of sun in summer, 
tanning lamp use, and 
radiation treatment did not 
alter estimates of 
photosensitizing 
medications effects and 
were not included in final 
models 
Schmidt et al. 
201514 
Case-
control 
study  
Northern Denmark 
using various 
registries linked by 
the CPR numbers; 
1991 to 2010; 
Denmark 
Maximum: 
19  
SCC: 2,282; 
BCC:17, 242, 
MM:3,660; 
controls:231,
743 
67 46 Aged ≥20 years with a 
first-time diagnosis of 
SCC, BCC, or MM and 
10 matched controls 
Use of 
antihyper
tensive 
drugs  
CCI score, hospital-
diagnosed obesity, and use 
of systemic glucocorticoids, 
aspirin, non-aspirin 
NSAIDs, and statins 
Christian et 
al. 200818 
Cohort 
study 
Veterans Affairs 
Topical Tretinoin 
Chemoprevention 
(VATTC) 
Median: 
3.4 years 
ACEi or ARB 
users: 532; 
non-users: 
519 
71 97 Enrolled 1131 veterans 
at high risk for BCC and 
SCC †; filled a 
prescription for at least 
Use of 
ACEi or 
ARB 
Age; sex; race; number of 
previous SCCs and BCCs 
in past 5 years; smoking 
history; sun sensitivity 
21  
Trial;1998 to 
2003;US 
one medication during 
the study period 
score; history of psoriasis, 
eczema, chemical peels, 
and 5-fluorouracil 
treatment; family history of 
skin cancer; education; 
arital status; number of 
actinic keratoses; CCI; and 
history of use of statins, H2 
blockers, antidepressants, 
and other antihypertensive 
agents. 
Moscarelli et 
al. 201025 
Cohort 
study 
Renal Unit 
Careggi University 
Hospital; 1991 to 
2005; Italy 
median: 
4.9 years 
ACEi or ARB 
users 215; 
non-users 
350 
60 66.4 All renal transplant 
recipients admitted to 
Renal Unit Careggi 
University Hospital, Italy 
from July 1991 to 
December 2005 
Use of 
ACEi or 
ARB for 
at least 
six 
months 
Sex, white race, smoking 
history, history of a 
previous 
SC, duration of pre-
transplant dialysis therapy, 
treatment for early acute 
rejection, age at transplant, 
number of years since 
transplantation, number of 
renal transplants, number 
of previous actinic 
keratosis, use of common 
antihypertensive 
medications, use of statins, 
histamine-H2 receptor 
antagonists, proton-pump 
inhibitors. 
Ruiter et al. 
201023 
Cohort 
study 
Rotterdam Study-
a large 
prospective, 
population-based 
follow-up study 
with coverage of 
prescription-only 
drugs from 
pharmacies;1986 
to 2007; 
Netherlands 
Maximum: 
20 years 
Use of high-
ceiling 
diuretics:110; 
no users: 412 
69 40 Patients received a 
prescription of diuretics 
before 1 April 1991  
Use of 
diuretics 
Gender, age, smoking 
status, self-reported 
tendency to sunburn, 
outdoor work, history of 
living in a country with a 
high sun exposure, 
ethnicity, natural hair color 
during childhood, natural 
hair color when adult, eye 
color, and cohort 
Kaae et al. 
201017 
Cohort 
study 
Danish national 
registers;1995 to 
2006; Denmark 
NR 4,761,749 
participants 
NR NR Patients identified from 
Danish Cancer Registers 
filled at least one 
prescription for 
Use of 
photosen
sitizing 
medicatio
n 
Age, period, sex, and 
education 
22  
photosensitizing 
medication 
(diuretics
) 
McDonald et 
al. 201413 
Cohort 
study 
United States 
Radiologic 
Technologists 
(USRT) Study; US 
8.7 years diuretics:685
9; no 
diuretics 
50716 
49 18 White participants from 
USRT study completed 
two questionnaires 
Use of 
diuretics 
Age, birth cohort, sex, 
continuous BMI, and UVR 
quartile 
Nardone et al. 
201624 
Cohort 
study 
Northwestern 
Medicine 
Enterprise Data 
Warehouse; 2004 
to 2015; US 
4 years ACEi: 27,134, 
Control:81,39
9; 
ARBs:13,818, 
Control:41,45
4;Thiazides: 
15,166, 
Control: 
45,498  
NR 43.4 Patient age range 18-89 
years, one or more 
written orders for an 
ACEi, ARB, or thiazides; 
3 matched individuals 
with no documented 
order for any 
antihypertensive drug 
Use of 
antihyper
tensive 
drugs 
(ACEi, 
ARB or 
thiazides) 
Age, gender, race, and CCI 
† high risk is defined as suffering from at least two BCCs and/or SCCs in the five years before the study periods. 2 
MM, malignant melanoma; BCC, basal cell carcinoma; SCC, squamous cell carcinoma; NR, not reported; ACEi, angiotensin converting enzyme inhibitors; ARBs, 3 
angiotensin II receptor blockers; β-blockers, beta-adrenergic blocking agents; CCBs, calcium channel blockers; NSAID, non-steroidal anti-inflammatory drug; CCI, 4 
charlson comorbidity index 5 
  6 
23  
Table 2. Subgroup analysis of use of diuretics and risk of KC  7 
Group/ 
subgroup 
BCC SCC 
No. of 
studies 
OR (95% CI) P value  I2 (%) No. of 
studies 
OR (95% CI) P value I2 (%) 
Total 8 1.10 (1.01, 1.20) 0.02 82.2 7 1.40 (1.19, 1.66) <0.01 81.8 
Design 
Cohort  5 1.09 (1.04, 1.13) <0.01 86 3 1.33 (1.24, 4.43) <0.01 92.8 
Case-control  3 1.02 (0.98, 1.06) 0.26 68.2 4 1.22 (1.12, 1.33) <0.01 4.5 
Region 
Europe 5 1.03 (0.98, 1.08) 0.24 54.3 4 1.26 (1.17, 1.36) <0.01 27.9 
USA 3 1.36 (0.94, 1.95) 0.10 87.9 3 1.78 (0.82, 3.87) 0.14 91.8 
Quality 
High 5 1.03 (0.98, 1.07) 0.26 45.2 4 1.25 (1.18, 1.32) <0.01 0 
Moderate 3 1.47 (1.04, 2.07) 0.03 83.9 3 2.06 (1.08, 3.93) 0.03 87.5 
Adjusted for sun or UVR exposure 
Yes 3 1.11 (1.00, 1.22) 0.05 50.1 2 1.17 (0.91, 1.51) 0.22 0 
No 5 1.13 (0.99,1.29) 0.07 87.6 5 1.49 (1.22,1.82) <0.01 87.4 
Adjusted for smoking status 
Yes 2 1.07 (1.01, 1.12) 0.01 0 1 1.09 (0.79,1.51) 0.60 - 
No 6 1.14 (1.02, 1.29) 0.03 87 6 1.46 (1.21, 1.75) <0.01 84.3 
 8 
24  
Figure legends:   
Figure 1. Flow chart of the identification of eligible studies  
Figure 2. Meta-analysis of the association between use of antihypertensive drugs and 
risk of BCC (A) and SCC (B). 
Figure 3. Cumulative meta-analysis of studies ordered by publication year for the 
association between use of diuretics and risk of BCC (A) and SCC (B). The studies are 
added at one time according to year of publication and the results are summarized as 
each new study is added. 
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